Insilico teams up with Boehringer Ingelheim on drug discovery

Research collaboration to apply generative AI system for discovery of potential therapeutic targets.

Artificial intelligence company Insilico Medicine has announced a research collaboration with pharmaceutical giant Boehringer Ingelheim. The companies will work together to identify potential therapeutic targets implicated in a variety of diseases using Insilico’s generative machine learning technology and its Pandomics Discovery Platform.

The Pandomics platform enables the development of comprehensive disease profiles that can be analysed for drug discovery and biomarker development, providing data on the highest scoring molecules and targets.

“Insilico Medicine is very impressed with the Research Beyond Borders group at Boehringer Ingelheim capabilities in the search of potential drug targets,” said Alex Zhavoronkov, PhD, founder, and CEO of Insilico Medicine. “In this collaboration, Insilico will provide additional AI capabilities to discover novel targets for a variety of diseases to benefit the patients worldwide. We are very happy to partner with such an advanced group.”


“In this collaboration, Insilico will provide additional AI capabilities to discover novel targets for a variety of diseases to benefit the patients worldwide…”



Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies with net sales of around $19 billion in 2018.

“We believe that Insilico’s exclusive Pandomics platform will provide huge boost to our ability to explore and identify drug targets,” said Dr. Weiyi Zhang, Head of External Innovation Hub, Boehringer Ingelheim Greater China. “We look forward to using AI to significantly improve the drug discovery process and contribute to human health.”

In January, Insilico Medicine announced a collaboration with skin care firm Beiersdorf to discover bioactive ingredients for skin indications.

Image credit: Tada Images / Shutterstock
Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.

Latest articles

Fountain’s ‘hypothesis-free’ approach to Longevity AI

We reached out to Fountain’s CEO John Dimos to see what more we can learn about the mysterious San Francisco start-up. When it comes to...

G3 and Juvenescence partner on deep learning venture

G3 Therapeutics and Juvenescence announce the formation of Juvenomics to apply deep molecular profiling and deep learning to tackle aging. Juvenomics, a joint venture between...

Building an artificial immune system

DoD-funded ThirdLaw Technologies to harness the power of ‘spiroligomers’ to rapidly build new small molecules for Longevity therapies. Far from the world of stock market...

Neurotech is the new blue ocean

Alon Braun, Co-Founder, Neurotech Analytics.